文献速递胸部肿瘤

早期非小细胞肺癌辅助化疗生存与高危临床病理特征的相关性

Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features.
PubMed 文献 · JAMA Oncol · 2020-01-01

结果显示,肿瘤≤3 cm时化疗与生存改善无关;肿瘤>3–4 cm时仅亚肺叶切除者获益;肿瘤>4–5 cm时仅合并至少1项高危病理特征者获益;肿瘤>5 cm时无论高危特征均获益。提示评估辅助化疗需同时考虑肿瘤大小与高危特征。

核心结论

  • 在淋巴结阴性早期非小细胞肺癌中,肿瘤大小本身与辅助化疗疗效改善无关。
  • 评估辅助化疗时应同时考虑高危临床病理特征与肿瘤大小。

研究设计与样本

  • 暴露为辅助化疗 vs 观察,并按高危病理特征(脏层胸膜侵犯、淋巴血管侵犯、高级别组织学)、亚肺叶手术和肿瘤大小分层;采用Cox比例风险回归模型评估生存关联。

临床怎么用

  • 对淋巴结阴性早期非小细胞肺癌评估辅助化疗时,应同时结合肿瘤大小与高危病理特征(脏层胸膜侵犯、淋巴血管侵犯、高级别组织学)。
  • 肿瘤≤3 cm者不应仅基于大小给予辅助化疗;肿瘤>4–5 cm者需确认至少1项高危特征再考虑辅助化疗;肿瘤>5 cm者可考虑辅助化疗。
  • 亚肺叶切除且肿瘤>3–4 cm者可能从辅助化疗中获益,可纳入个体化决策。

局限性

  • 为回顾性队列研究,可能存在选择偏倚和未测量混杂。
  • 数据来自美国国家癌症数据库,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tumor size larger than 4 cm is accepted as an indication for adjuvant chemotherapy in patients with node-negative non-small cell lung cancer (NSCLC). Treatment guidelines suggest that high-risk features are also associated with the efficacy of adjuvant chemotherapy among patients with early-stage NSCLC, yet this association is understudied. OBJECTIVE: To assess the association between adjuvant chemotherapy and survival in the presence and absence of high-risk pathologic features in patients with node-negative early-stage NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study using data from the National Cancer Database included 50 814 treatment-naive patients with a completely resected node-negative NSCLC diagnosed between January 1, 2010, and December 31, 2015. The study was limited to patients who survived at least 6 weeks after surgery (ie, estimated median time to initiate adjuvant chemotherapy after surgery) to mitigate immortal time bias. Statistical analysis was performed from December 1, 2018, to February 29, 2020. EXPOSURES: Adjuvant chemotherapy use vs observation, stratified according to the presence or absence of high-risk pathologic features (visceral pleural invasion, lymphovascular invasion, and high-grade histologic findings), sublobar surgery, and tumor size. MAIN OUTCOMES AND MEASURES: The association of high-risk pathologic features with survival after adjuvant chemotherapy vs observation was evaluated using Cox proportional hazards regression models. RESULTS: Overall, 50 814 eligible patients with NSCLC (27 365 women [53.9%]; mean [SD] age, 67.4 [9.5] years]) were identified, including 4220 (8.3%) who received adjuvant chemotherapy and 46 594 (91.7%) who did not receive adjuvant chemotherapy. Among patients with tumors 3 cm or smaller, chemotherapy was not associated with improved survival (hazard ratio [HR], 1.10; 95% CI, 0.96-1.26; P = .17). For patients with tumors larger than 3 cm to 4 cm, adjuvant chemotherapy was associated with a survival benefit among patients who underwent sublobar surgery (HR, 0.72; 95% CI, 0.56-0.93; P = .004). For tumors larger than 4 cm to 5 cm, a survival benefit was associated with adjuvant chemotherapy only in patients with at least 1 high-risk pathologic feature (HR, 0.67; 95% CI, 0.56-0.80; P = .02). For tumors larger than 5 cm, adjuvant chemotherapy was associated with a survival benefit irrespective of the presence of high-risk pathologic features (HR, 0.75; 95% CI, 0.61-0.91; P = .004). CONCLUSIONS AND RELEVANCE: In this cohort study, tumor size alone was not associated with improved efficacy of adjuvant chemotherapy in patients with early-stage (node-negative) NSCLC. High-risk clinicopathologic features and tumor size should be considered simultaneously when evaluating patients with early-stage NSCLC for adjuvant chemotherapy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Pathak R, Goldberg SB, Canavan M, et al. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncol. 2020. PMID: 32940636. doi:10.1001/jamaoncol.2020.4232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。